HER2 (ERBB2) mutations may increase receptor internalization and lead to hyperactive downstream signaling, uncontrolled cell growth, and tumorigenesis. Learn more about how HER2 mutations affect several types of cancer, including non-small cell lung cancer (NSCLC).

Intended for US Healthcare Professions only

©2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-8201a-1332 06/22